Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?

The Invesco Pharmaceuticals ETF (PJP), a passively managed fund with $257.58 million in assets, has returned 9.35% year-to-date and 6.41% over the past 12 months, tracking the Dynamic Pharmaceutical Intellidex Index. Despite its 0.56% expense ratio being on par with peers, PJP is considered a high-risk option due to its concentrated portfolio of 32 holdings, reflected in a 15.82% standard deviation, with Eli Lilly, Pfizer, and Amgen among its top constituents. While Zacks rates PJP a "Hold," investors seeking U.S. pharmaceutical exposure should consider alternatives like VanEck Pharmaceutical ETF (PPH) and iShares U.S. Pharmaceuticals ETF (IHE), which offer lower expense ratios and larger asset bases.

Analysis

The Invesco Pharmaceuticals ETF (PJP) provides concentrated exposure to the U.S. pharmaceutical sector, tracking the Dynamic Pharmaceutical Intellidex Index. While the fund has delivered positive returns, gaining 9.35% year-to-date and 6.41% over the last 12 months, its risk profile and cost structure warrant scrutiny. The ETF is labeled a high-risk choice due to a three-year standard deviation of 15.82%, a characteristic likely amplified by its concentrated portfolio of only 32 holdings, with the top 10 constituents accounting for 47.34% of total assets. Despite a low beta of 0.48 suggesting weak correlation to broader market movements, this high idiosyncratic volatility is a significant factor. Furthermore, its annual expense ratio of 0.56% is notably higher than direct competitors like the VanEck Pharmaceutical ETF (PPH) at 0.36% and the iShares U.S. Pharmaceuticals ETF (IHE) at 0.39%, both of which also command significantly larger assets under management. The neutral Zacks ETF Rank of 3 (Hold) reflects this mixed profile, positioning PJP as a sufficient but not necessarily optimal vehicle for pharma exposure when compared to more cost-effective and larger alternatives.

Key Decisions for Investors

• Investors seeking exposure to the pharmaceutical sector should compare PJP against lower-cost and larger alternatives like PPH and IHE before initiating a position.
• Current holders of PJP should be aware of its high-risk profile, driven by a 15.82% standard deviation and significant concentration in its top holdings, and assess if this aligns with their personal risk tolerance.